{"id":61921,"date":"2025-09-25T10:05:55","date_gmt":"2025-09-25T08:05:55","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/"},"modified":"2025-09-25T10:05:55","modified_gmt":"2025-09-25T08:05:55","slug":"sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/","title":{"rendered":"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium"},"content":{"rendered":"
\n

\n– Partner Curasense will market Equazen\u00ae<\/sup> products featuring a clinically researched combination of essential fatty acids across pharmacies, healthcare stores and online pharmacies.<\/b><\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

LUGANO, Switzerland–(BUSINESS WIRE)–#GLAsupplements<\/a>–SFI Health\u2122 EMEA, the regional entity of SFI Health\u2122, a global leader in natural healthcare, and Curasense BV (Curasense), a Belgian company specializing in the distribution and development of high-quality nutraceuticals and health products, are excited to announce that they have entered into an exclusive licensing agreement for Equazen\u00ae<\/sup> food supplements in the Netherlands and Belgium.<\/p>\n

\nUnder the terms of the agreement, Curasense will hold exclusive rights to distribute, promote, market, and sell Equazen\u00ae<\/sup> products within the licensed territories. Curasense will begin commercial activities following a transition period from SFI Health\u2122\u2019s previous licensee.<\/p>\n

\nTogether, Belgium and the Netherlands count over 6,500 pharmacies, alongside a strong presence of health stores \u2014 from 800 independents in Belgium to 2,000 outlets in the Netherlands. With well-established pharmacy and retail networks, plus growing online demand, the agreement positions the brand for strong visibility and reach across both markets.<\/p>\n

\nMatthew Brabazon, GM of SFI Health\u2122 EMEA<\/b> commented: \u201cWe are very pleased to collaborate with Curasense, a company with extensive experience in the healthcare sector and a strong reputation among healthcare professionals and consumers. This partnership marks an important step in strengthening the Equazen<\/i>\u00ae<\/sup> brand, as we leverage Curasense BV\u2019s expertise in bringing advanced scientifically naturally sourced health solutions to market. Together, we are committed to expand Equazen\u00ae<\/sup>\u2019s distribution and market share, establishing it as a reference point for brain health and cognitive wellness.\u201d<\/i><\/p>\n

\nMr. Jelle D\u2019Helft, CEO of Curasense,<\/b> added: \u201cWe are thrilled to formalize our strategic partnership with SFI Health\u2122 EMEA for the Equazen\u00ae brand in the Netherlands and Belgium. For Curasense, this agreement is a natural extension of our mission to deliver evidence-based health solutions that make a real impact. Equazen\u00ae<\/sup>\u2019s clinically supported formulations align closely with our vision and reflect our ambition to bridge conventional and complementary medicine. This collaboration will accelerate access to innovative, science-backed products for children, adolescents, and adults\u2014while setting new benchmarks in the nutraceutical industry.\u201d<\/i><\/p>\n

\nThe brain health supplement sector is emerging as one of the most dynamic segments within the global food supplements market. In Europe, it is expected to grow at a CAGR of 12.5% from 2023 to 2030, supported by increasing consumers\u2019 focus on sustaining normal cognitive function and mental health.<\/p>\n

\nEquazen\u00ae<\/sup> is currently present in several EMEA markets, including Spain, Portugal, the United Kingdom, Switzerland, Poland, the Czech Republic, Slovakia, the Nordics, and the Baltics, with SFI Health\u2122 aiming to broaden its reach into new markets to unlock its full sales potential and capitalize on the growing momentum in the brain food supplements sector.<\/p>\n

\nAbout SFI Health\u2122<\/b><\/p>\n

\nSFI Health\u2122 is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.<\/p>\n

\nGuided by the belief in the healing potential of natural products, SFI Health\u2122 <\/sup>combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.<\/p>\n

\nAn extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health\u2122 regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.<\/p>\n

\nSFI Health\u2122 is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.<\/p>\n

\nFor more information go to sfihealth.com<\/a> or follow us SFI Health<\/a> on LinkedIn.<\/p>\n

\nAbout Curasense<\/b><\/p>\n

\nCurasense BV is a Belgian company specializing in the distribution and development of high-quality nutraceuticals and health products. Building on more than 20 years of experience in the healthcare sector, Curasense delivers Health through Nature, Science and Innovation, addressing key needs like cognitive function, inflammation management, and overall vitality.<\/p>\n

\nThe company\u2019s approach combines a strong foundation in scientific substantiation and strict compliance with European regulations, ensuring proven quality and effectiveness.<\/p>\n

\nThrough close collaboration with international partners and healthcare professionals, consumers gain access to our innovative products.<\/p>\n

\nBased in Heist-op-den-Berg (Antwerp), Curasense serves both the Belgian and Dutch markets and continues to expand its ambition of making advanced health solutions available across Europe and beyond.<\/p>\n

\nFor more info go to curasense.com\/<\/a> or follow us Curasense<\/a> on LinkedIn.<\/p>\n

\nAbout Equazen<\/strong>\u00ae<\/sup><\/p>\n

\nEquazen<\/b>\u00ae<\/sup> is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain\u2019s potential across all life stages.<\/p>\n

\nEach product of the Equazen\u00ae<\/sup> range contains a balanced unique combination of essential fatty acids (Omega 3 and Omega 6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.<\/p>\n

\nEquazen\u00ae<\/sup> is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.<\/p>\n

\nCurrently marketed in 30 countries globally, Equazen\u00ae<\/sup> is widely recommended by healthcare professionals and trusted by families for the last 25 years.<\/p>\n

\nEquazen\u00ae<\/sup> aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.<\/p>\n

\nFor more info visit www.equazen.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information<\/b>
SFI Health\u2122 EMEA Contact<\/b>
Elisabetta Bianchi
\n
e-mail address: elisabetta.bianchi@sfihealth.com<\/a><\/p>\n

\nCurasense BV Contact<\/b>
Jelle D\u2019Helft
\n
e-mail address: jelle@curasense.be<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Partner Curasense will market Equazen\u00ae products featuring a clinically researched combination of essential fatty acids across pharmacies, healthcare stores and online pharmacies. LUGANO, Switzerland–(BUSINESS WIRE)–#GLAsupplements–SFI Health\u2122 EMEA, the regional entity of SFI Health\u2122, a global leader in natural healthcare, and Curasense BV (Curasense), a Belgian company specializing in the distribution and development of high-quality … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61921","6":"format-standard","7":"category-industry"},"yoast_head":"\nSFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Partner Curasense will market Equazen\u00ae products featuring a clinically researched combination of essential fatty acids across pharmacies, healthcare stores and online pharmacies. LUGANO, Switzerland–(BUSINESS WIRE)–#GLAsupplements–SFI Health\u2122 EMEA, the regional entity of SFI Health\u2122, a global leader in natural healthcare, and Curasense BV (Curasense), a Belgian company specializing in the distribution and development of high-quality ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-25T08:05:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250924776817\/en\/2589576\/22\/infographic_23-09-25.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium\",\"datePublished\":\"2025-09-25T08:05:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/\"},\"wordCount\":889,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250924776817\\\/en\\\/2589576\\\/22\\\/infographic_23-09-25.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/\",\"name\":\"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250924776817\\\/en\\\/2589576\\\/22\\\/infographic_23-09-25.jpg\",\"datePublished\":\"2025-09-25T08:05:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250924776817\\\/en\\\/2589576\\\/22\\\/infographic_23-09-25.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250924776817\\\/en\\\/2589576\\\/22\\\/infographic_23-09-25.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/","og_locale":"en_US","og_type":"article","og_title":"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium - Pharma Trend","og_description":"– Partner Curasense will market Equazen\u00ae products featuring a clinically researched combination of essential fatty acids across pharmacies, healthcare stores and online pharmacies. LUGANO, Switzerland–(BUSINESS WIRE)–#GLAsupplements–SFI Health\u2122 EMEA, the regional entity of SFI Health\u2122, a global leader in natural healthcare, and Curasense BV (Curasense), a Belgian company specializing in the distribution and development of high-quality ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/","og_site_name":"Pharma Trend","article_published_time":"2025-09-25T08:05:55+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250924776817\/en\/2589576\/22\/infographic_23-09-25.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium","datePublished":"2025-09-25T08:05:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/"},"wordCount":889,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250924776817\/en\/2589576\/22\/infographic_23-09-25.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/","url":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/","name":"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250924776817\/en\/2589576\/22\/infographic_23-09-25.jpg","datePublished":"2025-09-25T08:05:55+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250924776817\/en\/2589576\/22\/infographic_23-09-25.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250924776817\/en\/2589576\/22\/infographic_23-09-25.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sfi-health-emea-announces-exclusive-license-agreement-with-curasense-bv-for-equazen-in-the-netherlands-and-belgium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SFI Health\u2122 EMEA Announces Exclusive License Agreement with Curasense BV for Equazen\u00ae in the Netherlands and Belgium"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61921"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61921\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}